AbbVie (ABBV) Cash & Equivalents (2012 - 2026)
AbbVie (ABBV) reported Cash & Equivalents of $9.4 billion for Q1 2026, up 81.47% year-over-year from $5.2 billion in Q1 2025, and up 79.59% on a QoQ basis from $5.2 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Cash & Equivalents data on file, last reported at $9.4 billion in Q1 2026.
- Quarterly Cash & Equivalents rose 81.47% year-over-year to $9.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 billion (up 81.47% YoY) and the FY2025 annual result came in at $5.2 billion, down 5.34% from the prior year.
- Cash & Equivalents climbed to $9.4 billion in Q1 2026 per ABBV's latest filing, from $5.2 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $18.1 billion in Q1 2024 and bottomed at $5.2 billion in Q1 2025.
- The 5-year median for Cash & Equivalents is $8.5 billion (2022), against an average of $9.0 billion.
- The widest annual swing landed in 2024, when Cash & Equivalents surged 169.21%; it then tumbled 71.36% in 2025.
- Tracing ABBV's Cash & Equivalents over 5 years: stood at $9.2 billion in 2022, then soared by 39.27% to $12.8 billion in 2023, then tumbled by 56.89% to $5.5 billion in 2024, then fell by 5.34% to $5.2 billion in 2025, then jumped by 79.59% to $9.4 billion in 2026.
- Per Business Quant, the three latest ABBV Cash & Equivalents figures stand at $9.4 billion (Q1 2026), $5.2 billion (Q4 2025), and $5.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 4.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.39 Bn |
| Dec 31, 2025 | 5.23 Bn |
| Sep 30, 2025 | 5.63 Bn |
| Jun 30, 2025 | 6.47 Bn |
| Mar 31, 2025 | 5.18 Bn |
| Dec 31, 2024 | 5.52 Bn |
| Sep 30, 2024 | 7.26 Bn |
| Jun 30, 2024 | 13.13 Bn |
| Mar 31, 2024 | 18.07 Bn |
| Dec 31, 2023 | 12.81 Bn |
| Sep 30, 2023 | 13.29 Bn |
| Jun 30, 2023 | 8.76 Bn |
| Mar 31, 2023 | 6.71 Bn |
| Dec 31, 2022 | 9.20 Bn |
| Sep 30, 2022 | 11.83 Bn |
| Jun 30, 2022 | 8.52 Bn |
| Mar 31, 2022 | 6.10 Bn |
| Dec 31, 2021 | 9.75 Bn |
| Sep 30, 2021 | 12.18 Bn |
| Jun 30, 2021 | 8.55 Bn |
| Mar 31, 2021 | 9.76 Bn |
| Dec 31, 2020 | 8.45 Bn |
| Sep 30, 2020 | 7.89 Bn |
| Jun 30, 2020 | 6.02 Bn |
| Mar 31, 2020 | 41.14 Bn |
| Dec 31, 2019 | 39.92 Bn |
| Sep 30, 2019 | 10.65 Bn |
| Jun 30, 2019 | 5.17 Bn |
| Mar 31, 2019 | 4.90 Bn |
| Dec 31, 2018 | 7.29 Bn |
| Sep 30, 2018 | 8.02 Bn |
| Jun 30, 2018 | 3.55 Bn |
| Mar 31, 2018 | 9.01 Bn |
| Dec 31, 2017 | 9.30 Bn |
| Sep 30, 2017 | 8.45 Bn |
| Jun 30, 2017 | 6.09 Bn |
| Mar 31, 2017 | 4.74 Bn |
| Dec 31, 2016 | 5.10 Bn |
| Sep 30, 2016 | 6.22 Bn |
| Jun 30, 2016 | 6.33 Bn |
| Mar 31, 2016 | 7.56 Bn |
| Dec 31, 2015 | 8.40 Bn |
| Sep 30, 2015 | 9.22 Bn |
| Jun 30, 2015 | 7.40 Bn |
| Mar 31, 2015 | 7.91 Bn |
| Dec 31, 2014 | 8.35 Bn |
| Sep 30, 2014 | 7.72 Bn |
| Jun 30, 2014 | 9.09 Bn |
| Mar 31, 2014 | 8.14 Bn |
| Dec 31, 2013 | 9.60 Bn |
| Sep 30, 2013 | 8.98 Bn |
| Jun 30, 2013 | 8.74 Bn |
| Mar 31, 2013 | 6.98 Bn |
| Dec 31, 2012 | 5.90 Bn |
| Sep 30, 2012 | 2.76 Bn |
| Jun 30, 2012 | 74.00 Mn |
| Mar 31, 2012 | 41.00 Mn |